Jinhe Biotechnology CO., LTD. (SHE:002688)

Market Cap	5.20B
Revenue (ttm)	2.48B
Net Income (ttm)	106.17M
Shares Out	752.11M
EPS (ttm)	0.14
PE Ratio	50.25
Forward PE	28.79
Dividend	0.10 (1.45%)
Ex-Dividend Date	Jun 6, 2025

Volume	26,807,800
Average Volume	44,279,224
Open	6.97
Previous Close	6.91
Day's Range	6.78 - 6.97
52-Week Range	3.40 - 8.69
Beta	0.63
RSI	60.82
Earnings Date	Jul 31, 2025

About SHE:002688

Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. The company offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pneumonia, typhoid, paratyphoid, cholera, etc. in poultry and livestock; and chlortetracycline hydrochloride for the inhibition and treatment of pullorum disease, typhoid, and swine enteritis, as well as bacterial diseases, including paratyphoid and cholera. It also exports its products to the United States, South-east Asia, Latin Am...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 2,476
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002688

Financial Performance

In 2024, SHE:002688's revenue was 2.37 billion, an increase of 9.04% compared to the previous year's 2.17 billion. Earnings were 100.20 million, an increase of 15.90%.